CAS: 1604-14-4; 2,6-Dichloro-Isonicotinic Acid Ethyl Ester

相似化合物

5398-44-7 101990-69-6 113293-70-2

上下游产品

ethanol 2,6-dichloropyridine-4-carboxylic acid 2,6-dichloroisonicotinoyl chloride 3,5-dichloro-2(H)-1,4-oxazin-2-one5,5''-dimethyl-2,2':6',2''-terpyridine-4'-carboxylic acid ethyl ester 2-chloro-6-(5-cyano-2-benzyloxyphenoxy)pyridine-4-carboxylic acid ethyl ester (2,6-dichloropyridin-4-yl)methanol 6,6''-dimethyl-2,2':6',2''-terpyridine-4'-carboxylic acid ethyl ester

柠嗪酸置于硫酸,三乙胺,三氯氧磷体系中,化学反应生成2,6-二氯异烟酸乙酯
参考文献:Synthesis And Antimicrobial Activities Of Some Newly 2,4,6-Tri-Substituted Pyridine Derivatives
标题:Synthesis And Antimicrobial Activities Of Some Newly 2,4,6-Tri-Substituted Pyridine Derivatives
摘要:一系列新型2-(2-(取代亚苄基)肼基)-N'-(取代亚苄基)-6-氯吡啶-4-碳酰肼(5A-e),2-(2-环亚烷基肼基)-6-氯-N '-环亚烷基吡啶-4-碳酰肼 (6A,B),2-(2-(1-(4-取代的苯基)亚乙基)肼基)-6-氯-N'-(1-(4-取代的苯基)亚乙基)吡啶-4-碳酰肼 (7A,B) 和 2-(2-(1-(吡啶基)亚乙基)肼基)-6-氯-N'-(1-(吡啶基)亚乙基)吡啶-4-碳-通过用选定的活性试剂处理 2-氯-6-肼基异烟酸酰肼 4,合成了酰肼 (8A-c) 衍生物.它们的结构通过光谱和分析数据得到证实.研究了合成化合物的抗菌活性.抗菌筛选表明,所获得的许多化合物具有与链霉素和夫西地酸作为参考药物相当的非常好活性.
Doi:10.1007/s11164-013-1028-0

专利信息

专利号:US-2025304580-A1
优先权日:2021-11-09
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:WO-2014158302-A1
优先权日:2013-03-25
标 题:Novel sphingosine 1-phosphate receptor antagonists
发明人：SWENSON ROLF ERIC
权利人:SWENSON ROLF ERIC
摘要:The present invention relates to sphingosine-1 -phosphate (S1 P) receptors and compounds of the general formula (1), that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1 -phosphate receptor 2 (S1 P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1 P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1 P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.

专利号:US-9663511-B2
优先权日:2012-03-26
标题:Sphingosine 1-phosphate receptor antagonists
发明人：SWENSON ROLF E
权利人:ARROYO BIOSCIENCES LLC
摘要:The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: n nthat are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (S1P 2 ) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1P 2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1P 2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.